When EyePoint Pharmaceuticals decided to dramatically expand its manufacturing capacity to meet the growing needs of their patients, the company turned to RP Masiello to lead the design/build program for a new 40,000 sq. ft. manufacturing facility.

From start to finish, the project demanded exacting detail so the facility would meet the rigorous requirements of current Good Manufacturing Practices (cGMP), which is necessary for EyePoint to comply with U.S. FDA and European Medicines Agency (EMA) standards for producing therapeutics.

Construction began in the spring of 2023 and was completed in the summer of 2024.
EyePoint’s new facility includes 10 production suites for clinical supply and commercial scale manufacturing of approved products, plus laboratory support space, all built to ISO 7 clean room standards. The facility includes Quality Control and Quality Assurance (QC/QA) functions and administrative spaces to support the growth of their global business.